Last year, Ochre Bio sat down (virtually) with Eduardo Martins, (who is now the CMO at Sagimet Biosciences), to discuss the challenges of clinical development in NASH/NAFLD and Ochre Bio’s novel approach. Eduardo has over 20 years of experience in biotech and pharma and has a proven track record in building and leading multi-functional global teams, as exemplified by his time as VP, Clinical Development at Abbvie. We are thrilled to have him as an advisor to the company.

In our discussion, Eduardo highlighted the importance of Ochre’s approach of rejuvenating livers for transplantation.

“Ochre Bio has revolutionary potential in…

2020 will be remembered as the year of RNA blockbusters, including both COVID-19 vaccines and Novartis’ Leqvio. While the traditional view of RNA, developed by Francis Crick in the 1950’s, was merely as a messenger between DNA and protein, further research has since demonstrated the critical role of RNA as a commander within the cell.

Drug makers have been constrained by their limited understanding of how proteins function, or more specifically dysfunction within cells, but targeting RNA allows them to move upstream of proteins, creating new, functional proteins and ‘turning off’ dysfunctional ones.

Ochre Bio

Phenomics-led RNA medicines for chronic liver diseases

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store